Literature DB >> 12013151

Chondroitin sulfate in erosive osteoarthritis of the hands.

G Rovetta1, P Monteforte, G Molfetta, V Balestra.   

Abstract

The aim of this study was to evaluate the joint count for erosions in patients with erosive osteoarthritis (EOA) of the hands treated with 800 mg/day of orally administered chondroitin sulfate plus naproxen, compared with that of patients administered naproxen only. Twenty-four consecutive patients (22 women and two men, mean age 53.0 +/- 6) suffering from symptomatic OA and with radiographic characteristics of EOA were studied. The patients were divided into two groups of 12 patients each. The first group took naproxen 500 mg/day only. The second group was treated with chondroitin sulfate 800 mg/day orally plus naproxen 500 mg/day. Radiological hand examinations were performed at baseline and again after 12 and 24 months. In both groups, the joint count for erosions showed a general tendency to increase over time. Progression of erosions at 24 months was lower in patients treated with 800 mg/day chondroitin sulfate plus naproxen than in patients taking naproxen only (p <0.05). Chondroitin sulfate failed to stop the usual time-associated progression in the number of finger joints presenting erosions in EOA of the hands. It was, however, associated with a lower increase in the number of finger joints with erosions detected after 2 years of radiological observation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12013151

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  10 in total

Review 1.  Erosive osteoarthritis: A systematic analysis of definitions used in the literature.

Authors:  David J Gazeley; Supraja Yeturi; Payal J Patel; Ann K Rosenthal
Journal:  Semin Arthritis Rheum       Date:  2016-08-24       Impact factor: 5.532

Review 2.  Chondroitin for osteoarthritis.

Authors:  Jasvinder A Singh; Shahrzad Noorbaloochi; Roderick MacDonald; Lara J Maxwell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

Review 3.  Pharmacological therapies for osteoarthritis of the hand: a review of the evidence.

Authors:  Roy D Altman
Journal:  Drugs Aging       Date:  2010-09-01       Impact factor: 3.923

Review 4.  Hand osteoarthritis-nonpharmacological and pharmacological treatments.

Authors:  Margreet Kloppenburg
Journal:  Nat Rev Rheumatol       Date:  2014-01-28       Impact factor: 20.543

Review 5.  Erosive osteoarthritis: a current review of a clinical challenge.

Authors:  Sharon E Banks
Journal:  Clin Rheumatol       Date:  2010-01-28       Impact factor: 2.980

6.  Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study.

Authors:  Antonella Fioravanti; Marta Fabbroni; Alfonso Cerase; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2009-02-06       Impact factor: 2.631

7.  EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; B F Leeb; L Alekseeva; N K Arden; J W Bijlsma; F Dinçer; K Dziedzic; H J Häuselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; E Maheu; E Martín-Mola; K Pavelka; L Punzi; S Reiter; J Sautner; J Smolen; G Verbruggen; I Zimmermann-Górska
Journal:  Ann Rheum Dis       Date:  2006-10-17       Impact factor: 19.103

Review 8.  Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment.

Authors:  Jean-Yves Reginster; Nicola Veronese
Journal:  Aging Clin Exp Res       Date:  2020-07-07       Impact factor: 3.636

9.  Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.

Authors:  H Richard Barthel; John H Peniston; Michael B Clark; Morris S Gold; Roy D Altman
Journal:  Arthritis Res Ther       Date:  2010-01-11       Impact factor: 5.156

Review 10.  Immunomodulatory and anti-inflammatory effects of chondroitin sulphate.

Authors:  Patrick du Souich; Antonio G García; Josep Vergés; Eulàlia Montell
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.